title: Regional variation in medication following coronary events in Germany.
abstract: BACKGROUND
  Mortality rates from ischaemic heart disease have consistently been higher in East compared to West Germany both prior to and since reunification. Coronary care is inversely related to mortality from ischaemic heart disease. The objective of the present study was, therefore, to compare cardiovascular medication in East and West German patients following cardiac rehabilitation.
  
  
  METHODS
  East German (n = 530) and West German (n = 1638) patients were included at admission to one of 18 rehabilitation centres. Inclusion criteria were myocardial infarction, coronary artery bypass grafting and percutaneous transluminal coronary angioplasty. The follow-up period was 12 months.
  
  
  RESULTS
  At admission, East and West German patients differed with regard to sociodemographic variables, risk factors and medical conditions. At 12 months, a higher percentage of West compared to East German patients were prescribed beta-blockers (71% vs. 65%, P = 0.04) and lipid-lowering agents (64% vs. 55%, P = 0.002). Angiotensin converting enzyme (ACE) inhibitors, on the other hand, were prescribed more frequently in the East compared to the West (60% vs. 48%, P < 0.001). In multivariable analyses, region of residence remained a significant predictor for the prescription of lipid-lowering agents (East vs. West: OR 0.61, 95% CI 0.46-0.81) and ACE inhibitors (East vs. West: OR 1.78, 95% CI 1.33-2.39).
  
  
  CONCLUSIONS
  There is a considerable variation in the prescription of cardiovascular medication in secondary prevention within Germany. Some, but not all, of this variation can be explained by differences in patient characteristics.
authors.affiliation: Institute of Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, D-10098 Berlin, Germany. jacqueline.muller-nordhorn@charite.de
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Müller-Nordhorn
authors.forename: Michael
authors.initials: M
authors.lastname: Kulig
authors.forename: Sylvia
authors.initials: S
authors.lastname: Binting
authors.forename: Heinz
authors.initials: H
authors.lastname: Völler
authors.forename: Karl J
authors.initials: KJ
authors.lastname: Krobot
authors.forename: Stefan N
authors.initials: SN
authors.lastname: Willich
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003327:Coronary Disease / Q000401:mortality / Q000534:rehabilitation*; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D005260:Female; D005500:Follow-Up Studies; D005859:Germany, East / Q000453:epidemiology; D005860:Germany, West / Q000453:epidemiology; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011446:Prospective Studies; D017062:Small-Area Analysis; D015996:Survival Rate / Q000639:trends
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000960:Hypolipidemic Agents